Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | AKT2 | P31751 | 1/20 | 0.35 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 6/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30928408 | 1.00 | ACLY (0.37) | ACLYPIK3CAAKT1AKT2AKT3 | |
| SCHEMBL30889635 | 0.89 | ACLY (0.36) | ACLYPIK3CAAKT1AKT2AKT3 | |
| SCHEMBL30928463 | 0.89 | ACLY (0.36) | ACLYPIK3CAAKT1AKT2AKT3 | |
| SCHEMBL27009554 | 0.89 | AURKA (0.35) | ACLYPIK3CAAKT1AKT2AKT3 | |
| SCHEMBL31481682 | 0.89 | AURKA (0.35) | ACLYPIK3CAAKT1AKT2AKT3 | |
| SCHEMBL26881431 | 0.89 | AURKA (0.35) | ACLYPIK3CAAKT1AKT2AKT3 | |
| SCHEMBL27008442 | 0.87 | PIK3CA (0.44) | PIK3CAAKT1AKT2AKT3MAP4K1 | |
| SCHEMBL27148738 | 0.87 | PIK3CA (0.44) | PIK3CAAKT1AKT2AKT3MAP4K1 | |
| SCHEMBL30889717 | 0.86 | PIK3CA (0.38) | ACLYPIK3CAAKT1AKT2AKT3 | |
| SCHEMBL30928420 | 0.84 | KDM5B (0.37) | PIK3CAAKT1AKT2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182460-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION | 2024-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182460-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | ACLY 2561/4885PIK3CA 1/4885AKT1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.